Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helin forming oligonucleotide directed against androgen receptor

Chinese Medical Journal

Volumn 121, Issue 22, 2008, Pages 2284-2289

  Zhang, Yong ^a   Ma, Yi ^a   Lu, Han Ping ^a   Gao, Jin Hui ^a   Liang, Chang Sheng ^a   Liu, Chang Zheng ^a   Zou, Jun Tao ^a   Wang, Hua Qiao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Androgen receptor; Gene therapy; Iodine radioisotopes; Oligonucleotides; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; OLIGONUCLEOTIDE IODINE 125; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG TARGETING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE HELIX; XENOGRAFT;

EID: 62749131630     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200811020-00014     Document Type: Article

References (20)

1. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003; 170: 1717-1721.
2. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351: 1488-1490.
3. Culig Z, Steiner H, Bartsch G, Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr Relat Cancer 2005; 12: 229-244.
4. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62: 1008-1013.
5. Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002; 9: 117-125.
6. Tong QS, Zhao J, Chen ZH, Zeng FQ, Lu GC. Effects of blocking androgen receptor expression with specific hammerhead ribozyme on in vitro growth of prostate cancer cell line. Chin Med J 2003; 116: 1515-1518.
7. Jiang J, Wang LF, Fang YH, Jin FS, Jin WS. Proliferative response of human prostate cancer cell to hormone inhibited by androgen receptor antisense RNA. Chin Med J 2004; 117: 684-688.
8. Santos AF, Huang H, Tindall DJ. The androgen receptor: a potential target for therapy of prostate cancer. Steroids 2004; 69: 79-85.
9. Kageyama Y, Hyochi N, Kihara K, Sugiyama H. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer. Recent Patents Anticancer Drug Discov 2007; 2: 203-211.
10. Faria M, Wood CD, Perrouault L, Nelson JS, Winter A, White MR, et al. Targeted inhibition of transcription elongation in cells mediated by triplex-forming oligonucleotides. Proc Natl Acad Sci USA 2000; 97: 3862-3867.
11. Besch R, Giovannangeli C, Degitz K. Triplex-forming oligonucleotides-sequence-specific DNA ligands as tools for gene inhibition and for modulation of DNA-associated functions. Curr Drug Targets 2004; 5: 691-703.
12. 125I-triplex-forming oligonucleotides as a measure of their succesful delivery into cell nuclei. Ann N Y Acad Sci 2005; 1058: 140-150.
13. 125I labeled anti-androgen receptor agent on the proliferation of prostate cancer cells. Chin J Nucl Med (Chin) 2007; 27:10-12.
14. Praseuth D, Guieysse, AL, Helene C. Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochim Biophys Acta 1999; 1489: 181-206.
15. 125I-labeled triplex-forming oligonucleotides. Ann N Y Acad Sci 2003; 1002: 134-140.
16. Martin RF, Haseltine WA. Range of radiochemical damage to DNA with decay of iodine-125. Science 1981; 213: 896-898.
17. Shen CX, Buck A, Polat B, Schmid-Kotsas A, Matuschek C, Gross HJ, et al. Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells. Cancer Gene Ther 2003; 10: 403-410.
18. Carbone GM, Napoli S, Valentini A, Cavalli F, Watson DK, Catapano CV. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res 2004; 32: 4358-4367.
19. Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1998; 240: 324-326.
20. Ebara S, Katayama T, Tanimoto R, Edamura K, Nose S, Manabe D, et al. Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer. Acta Med Okayama 2008; 62: 9-13.